Logo image
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
Journal article   Open access   Peer reviewed

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease

Andrew McGarry, Michael McDermott, Karl Kieburtz, Elisabeth A de Blieck, Flint Beal, Karen Marder, Christopher Ross, Ira Shoulson, Peter Gilbert, William M Mallonee, …
Neurology, Vol.88(2), pp.152-159
01/10/2017
DOI: 10.1212/WNL.0000000000003478
PMCID: PMC5224719
PMID: 27913695
url
https://europepmc.org/articles/pmc5224719View
Published (Version of record) Open Access

Abstract

To test the hypothesis that chronic treatment of early-stage Huntington disease (HD) with high-dose coenzyme Q10 (CoQ) will slow the progressive functional decline of HD. We performed a multicenter randomized, double-blind, placebo-controlled trial. Patients with early-stage HD (n = 609) were enrolled at 48 sites in the United States, Canada, and Australia from 2008 to 2012. Patients were randomized to receive either CoQ 2,400 mg/d or matching placebo, then followed for 60 months. The primary outcome variable was the change from baseline to month 60 in Total Functional Capacity score (for patients who survived) combined with time to death (for patients who died) analyzed using a joint-rank analysis approach. An interim analysis for futility revealed a conditional power of <5% for the primary analysis, prompting premature conclusion in July 2014. No statistically significant differences were seen between treatment groups for the primary or secondary outcome measures. CoQ was generally safe and well-tolerated throughout the study. These data do not justify use of CoQ as a treatment to slow functional decline in HD. NCT00608881. This article provides Class I evidence that CoQ does not slow the progressive functional decline of patients with HD.
Australia Canada United States Adult Double-Blind Method Female Humans Huntington Disease - drug therapy International Cooperation Male Middle Aged Proportional Hazards Models Retrospective Studies Treatment Outcome Ubiquinone - analogs & derivatives Ubiquinone - therapeutic use Vitamins - therapeutic use

Details

Metrics

Logo image